Relevance: Every year, 732,210 new cases of RC are registered globally, with an incidence of 7.6 per 100,000. The COVID-19 pandemic has affected the screening, case detection, and referral of patients with an asymptomatic cancer diagnosis. The aim was to assess the trends in rectal cancer incidence in the entire population of Kazakhstan before and during the COVID pandemics. Methods: The data obtained from the Ministry of Healthcare of the Republic of Kazakhstan concerning RC (Form no. 7) was retrospectively studied by descriptive and analytical epidemiology methods. The component method was used to analyze RC incidence dynamics based on the number of cases from 2010 to 2020. Results: From 2010 to 2020, the risk of getting RC went down. An increase in incidence in 2010-2020 (+24.8%) was lower than in the preCOVID period of 2010-2019 (+37.2%). We found a sharp decrease in RC incidence from 2019 to 2020. The overall decrease was 0.89‰⁰⁰ due to changes in the age structure of the population (∑ΔA=+0.13‰⁰⁰), the risk of getting RC (∑ΔR=−1.02‰⁰⁰), and the combined impact of age structure and the risk of getting RC (∑ΔAR=−0.002‰⁰⁰). According to the component analysis, 1,662 patients with RC were expected in 2020; instead, only 1,471 cases were registered. Such a decline in cases was mainly due to a reduced risk of getting RC. Conclusions: The analysis of RC incidence trends in Kazakhstan shows a negative impact of COVID-19 on cancer care indicators and effectiveness. All oncological examinations were strengthened with the resumption of work after COVID restrictions. However, the number of screening visits remains lower than in previous years. Untimely diagnosis can increase the number of cases of late-stage CRC and an overall loss of years of life due to the lack of proper treatment. However, these forecasts can be mitigated by proper follow-up
Relevance: Every year, 732,210 new cases of RC are registered globally, with an incidence of 7.6 per 100,000. The COVID-19 pandemic has affected the screening, case detection, and referral of patients with an asymptomatic cancer diagnosis. The aim was to assess the trends in rectal cancer incidence in the entire population of Kazakhstan before and during the COVID pandemics. Methods: The data obtained from the Ministry of Healthcare of the Republic of Kazakhstan concerning RC (Form no. 7) was retrospectively studied by descriptive and analytical epidemiology methods. The component method was used to analyze RC incidence dynamics based on the number of cases from 2010 to 2020. Results: From 2010 to 2020, the risk of getting RC went down. An increase in incidence in 2010-2020 (+24.8%) was lower than in the preCOVID period of 2010-2019 (+37.2%). We found a sharp decrease in RC incidence from 2019 to 2020. The overall decrease was 0.89‰⁰⁰ due to changes in the age structure of the population (∑ΔA=+0.13‰⁰⁰), the risk of getting RC (∑ΔR=−1.02‰⁰⁰), and the combined impact of age structure and the risk of getting RC (∑ΔAR=−0.002‰⁰⁰). According to the component analysis, 1,662 patients with RC were expected in 2020; instead, only 1,471 cases were registered. Such a decline in cases was mainly due to a reduced risk of getting RC. Conclusions: The analysis of RC incidence trends in Kazakhstan shows a negative impact of COVID-19 on cancer care indicators and effectiveness. All oncological examinations were strengthened with the resumption of work after COVID restrictions. However, the number of screening visits remains lower than in previous years. Untimely diagnosis can increase the number of cases of late-stage CRC and an overall loss of years of life due to the lack of proper treatment. However, these forecasts can be mitigated by proper follow-up.
Objective: The aim is to study the trends in colorectal cancer (CRC) mortality in Kazakhstan. Methods: The retrospective study was done using descriptive and analytical methods of oncoepidemiology. The extensive, crude and age-specific mortality rates are determined according to the generally accepted methodology used in sanitary statistics. Results: CRC mortality in Kazakhstan is considered to be increasing. Therefore, this study (for the period 2009-2018) was undertaken to retrospectively evaluate data across the country available from the central registration bureau. Age standardized data for mortality was generated and compared across age groups. It was determined that during the studied period 15,200 died of this pathology. During the studied years an average age of the dead made 69.8 years (95%CI=69.5-70.0). The average annual standardized mortality rate was 10.2 per 100,000, and in dynamics tended to decrease. Peak of mortality was noted in aged 60-84 years. Trends in age-related mortality rates had a pronounced tendency to increase in 30-34 years (T=+11.7%, R 2 =0.7980) and to decrease in 75-79 years (T=–16.4%, R 2 =0.8881). In many regions, there is a decrease in the number of deaths. During the compilation of cartograms, mortality rates were determined on the basis of standardized indicators: low – up to 8.9, average – from 8.9 to 11.5, high – above 11.5 per 100,000 for the entire population. In addition, all calculations were made taking into account age-sex differences. Conclusion: Trends in mortality from CRC in recent years have decreased from 11.2 to 7.7 per 100,000 of the total population, while the trend is stable (T=−3.6%, R 2 =0.8745). The study of regional mortality has theoretical and practical significance: monitoring and evaluation of the effectiveness of early detection and treatment of detected pathology. Health authorities should take into account the results obtained when organizing anti-cancer measures.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.